Each unit consists of one common share and one-half of one common share purchase warrant, with each whole common share purchase warrant entitling the holder to purchase one common share at a price of C$2.36 for up to three years after the closing date of the private placement.
John Docherty, president of Helix BioPharma, said: “This is an exciting time for Helix as we open clinical trial sites in Germany for our trial of topical interferon alpha-2b for the treatment of ano-genital warts, prepare for additional clinical trials for this treatment and continue to progress towards clinical testing with L-DOS47. We plan to use the proceeds from the placement for working capital, primarily to support these R&D initiatives.”